What is a stock summary page? Click here for an overview.
Business Description
Santhera Pharmaceuticals Holding AG
NAICS : 325414
ISIN : CH1276028821
Description
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives the majority of its revenue from the European Union.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.63 | |||||
| Equity-to-Asset | 0.44 | |||||
| Debt-to-Equity | 0.55 | |||||
| Debt-to-EBITDA | 0.31 | |||||
| Interest Coverage | 3.1 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | -2.23 | |||||
| Beneish M-Score | 8.46 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -5.6 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 64.25 | |||||
| 9-Day RSI | 53.81 | |||||
| 14-Day RSI | 49.62 | |||||
| 3-1 Month Momentum % | 3.81 | |||||
| 6-1 Month Momentum % | 61.58 | |||||
| 12-1 Month Momentum % | 52.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.63 | |||||
| Quick Ratio | 0.52 | |||||
| Cash Ratio | 0.31 | |||||
| Days Inventory | 219.24 | |||||
| Days Sales Outstanding | 13.76 | |||||
| Days Payable | 507.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -84.1 | |||||
| Shareholder Yield % | 2.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 94.26 | |||||
| Operating Margin % | 47.3 | |||||
| Net Margin % | 55.34 | |||||
| FCF Margin % | 41.62 | |||||
| ROE % | 289.04 | |||||
| ROA % | 67.12 | |||||
| ROIC % | 46.41 | |||||
| 3-Year ROIIC % | 568.57 | |||||
| ROC (Joel Greenblatt) % | 5782.92 | |||||
| ROCE % | 227.33 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 2.47 | |||||
| PE Ratio without NRI | 4.08 | |||||
| Price-to-Owner-Earnings | 2.98 | |||||
| PS Ratio | 1.33 | |||||
| PB Ratio | 3.45 | |||||
| Price-to-Free-Cash-Flow | 3.16 | |||||
| Price-to-Operating-Cash-Flow | 3.15 | |||||
| EV-to-EBIT | 2.34 | |||||
| EV-to-Forward-EBIT | -20.01 | |||||
| EV-to-EBITDA | 2.24 | |||||
| EV-to-Forward-EBITDA | -40.02 | |||||
| EV-to-Revenue | 1.66 | |||||
| EV-to-Forward-Revenue | 5.32 | |||||
| EV-to-FCF | 3.62 | |||||
| Earnings Yield (Greenblatt) % | 42.62 | |||||
| FCF Yield % | 26.43 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Santhera Pharmaceuticals Holding AG Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 113.589 | ||
| EPS (TTM) (CHF) | 5.75 | ||
| Beta | -2.63 | ||
| 3-Year Sharpe Ratio | 0.33 | ||
| 3-Year Sortino Ratio | 0.89 | ||
| Volatility % | 79.87 | ||
| 14-Day RSI | 49.62 | ||
| 14-Day ATR (CHF) | 0.675444 | ||
| 20-Day SMA (CHF) | 14.193 | ||
| 12-1 Month Momentum % | 52.58 | ||
| 52-Week Range (CHF) | 7.7 - 17.54 | ||
| Shares Outstanding (Mil) | 12.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Santhera Pharmaceuticals Holding AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Santhera Pharmaceuticals Holding AG Stock Events
| Event | Date | Price (CHF) | ||
|---|---|---|---|---|
| No Event Data | ||||
Santhera Pharmaceuticals Holding AG Frequently Asked Questions
What is Santhera Pharmaceuticals Holding AG(LTS:0QN1)'s stock price today?
The current price of LTS:0QN1 is CHF14.22. The 52 week high of LTS:0QN1 is CHF17.54 and 52 week low is CHF7.70.
When is next earnings date of Santhera Pharmaceuticals Holding AG(LTS:0QN1)?
The next earnings date of Santhera Pharmaceuticals Holding AG(LTS:0QN1) is .
Does Santhera Pharmaceuticals Holding AG(LTS:0QN1) pay dividends? If so, how much?
Santhera Pharmaceuticals Holding AG(LTS:0QN1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers